Highest-materiality recent filing
Scienture shareholders reject 20x authorized share increase; approve reverse split and equity plan
Proposal to boost authorized common shares from 100M to 2B and preferred from 10M to 200M was rejected (5.3M for, 5.5M against).
Scienture increases at-the-market equity facility to $150M via Maxim Group
Maximum aggregate offering price under ATM agreement raised to $150 million; entire amount remains available as of Nov 7, 2025.
Scienture receives Nasdaq delisting notice for bid price below $1.00
Notice received Oct 14, 2025 for non-compliance with Nasdaq Listing Rule 5450(a)(1).
Scienture refinances $2.7M NVK loan with $3.9M Streeterville note, issues 250K shares
Entered $3,911,111 senior secured note (net $3.5M) with Streeterville Capital; 9% interest, 7-month term.
Scienture Holdings converts $559K debentures to equity at $2.4861/share, terminates Arena debt
Conversion price of 10% OID secured debentures amended to $2.4861 per share.
Scienture Holdings enters $9.2M ATM equity distribution agreement with Maxim Group
Total gross sales price up to $9.2M under shelf registration (Form S-3).
Scienture raises ~$3.9M via registered direct offering of 3.225M shares at $1.20/share
Offering of 3,225,000 shares at $1.20/share for gross proceeds of ~$3.9M; closed August 15, 2025.
Scienture raises up to $3M in bridge funding; secures $1.2M initially
Board approved capital raise of up to $3M; Company sold 754,716 shares at $1.59 per share.
Scienture Holdings CEO and President resign; Nasdaq bid-price deficiency received
CEO Suren Ajjarapu and Chairman resigned May 16; President Prashant Patel resigned May 20, both no disputes.
On May 16, 2025, as part of a planned leadership succession, Suren Ajjarapu advised the Company that he was resigning from his position as the Company’s Chief Executive Officer and Chairman of the Board effective immediately.
the Company’s board of directors appointed Dr. Narasimhan Mani, age 50, and Dr. Shankar Hariharan, age 68, to serve as co-Chief Executive Officers of the Company effective as of May 20, 2025.
As part of the planned leadership transition, Prashant Patel also advised the Company that he was resigning from his position as the Company’s President and Chief Operating Officer, effective as of May 20, 2025.
The board of directors also appointed Dr. Mani to serve as a director on the Company’s board of directors to fill the vacancy created as a result of Mr. Ajjarapu’s resignation and appointed Dr. Hariharan to the position of Executive Chairman of the Company’s board of directors, each effective as of May 20, 2025.
Max materiality 0.75 · Median 0.60 · Most common event other_material